1.World Health Organization. Global tuberculosis report 2015 (WHO). 2015.Available at: www.who.int/about/ licensing/copyright_form/en/index.html.
2. Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus calmette-guerin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 2008; 12:e99–e105.
3. Logan KE, Chambers MA, Hewinson RG, Hogarth PJ. Frequency of IFN-gamma producing cells correlates with adjuvant enhancement of Bacille Calmette-Guerin induced protection against Mycobacterium bovis. Vaccine 2005; 23:5526–5532.
4. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol 2013; 31:475-527.
5. Liljeqvist S, Ståhl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 1999; 73:1-33.
6. Guo S, Xue R, Li Y, Wang SM, Ren L, Xu JJ. The CFP10/ESAT6 complex of Mycobacterium tuberculosis may function as a regulator of macrophage cell death at different stages of tuberculosis infection. Med Hypotheses 2012; 78:389-392.
7. Guinn KM, Hickey MJ, Mathur SK, Zakel KL, Grotzke JE, Lewinsohn DM, et al. RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol 2004; 51:359-370.
8. Ganguly N1, Siddiqui I, Sharma P. Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence. Tuberculosis 2008; 88:510-517.
9. Ottenhoff TH, Kaufmann SH. Vaccines against Tuberculosis: where are we and where do we need to go? PLoS Pathog 2012; 8:e1002607.
10. Soleimanpour S, Hassannia T, Motiee M, Amini AA, Rezaee SA. Fcy1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. Crit Rev Biotechnol 2016; 6:1–22.
11. Soleimanpour S, Farsiani F, Mosavat A, Ghazvini K, Eydgahi MR, Sankian M, et al. APC targeting enhances immunigenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. Appl Microbiol Biotechnol 2015; 99:10467–10480.
12. Adamova E, Walsh MC, Gosselin DR, Hale K, Preissler MT, Graziano RF, et al. Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human Fc-gamma receptor type I using an anti-human Fc-gamma receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunol Invest 2005; 34:417–429.
13. Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van De Winkel JG, Deo YM, et al. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol 2000; 165:6738–6742.
14. den Haan JM, Lehar SM, Bevan MJ. CD8 (+) but not CD8 (-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192:1685–1696.
15. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680–685.
16. Mosavat A, Soleimanpour S, Farsiani H, Sadeghian H, Ghazvini K, Sankian M, et al. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine. Infect Genet Evol 2016; 39:163–172.
17. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718:22–31.
18. Farsiani H, Mosavat A, Soleimanpour S, Sadeghian H, Akbari Eydgahi MR, Ghazvini K, et al. Fc-based delivery system enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the ESAT-6:CFP-10 complex. Mol Biosyst 2016; 12:2189-2201.
19. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249–2254.
20. Herbst S, Schaible UE, Schneider BE. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS One 2011; 6:e19105.
21. Méndez-Samperio P. Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease. Int J Infect Dis 2010; 14:e366-371.
22. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010; 21:455–462.
23. Harris J, De Haro SA, Master SS, Keane J, Roberts EA, Delgado M, et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007; 27:505–517.
24. Ansel KM, Lee DU, Rao A. An epigenetic view of helper T cell differentiation. Nat Immunol 2003; 4:616–623.
25. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helpercell differentiation. Nat Rev Immunol 2009; 9:91–105.
26. Wu Y, Woodworth JS, Shin DS, Morris S, Behar SM. Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection. Infect Immun 2008; 76:2249-2255.
27. Li W, Deng G, Li M, Zeng J, Zhao L, Liu X, et al. A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice. Mol Immunol 2014; 62:86-95.
28. Braren I, Greunke K, Umland O, Deckers S, Bredehorst R, Spillner E. Comparative expression of different antibody formats in mammalian cells and Pichia pastoris. Biotechnol Appl Biochem 2007; 47:205–214.
29. Guo Y, Kang W, Zhong Y, Li R, Li G, Shen Y, et al. Purification and characterization of human IL-10/Fc
fusion protein expressed in Pichia pastoris. Protein Expr Purif 2012; 83:152–156.
30. Li P, Anumanthan A, Gao XG, Ilangovan K, Suzara VV, Duzgunes N, et al. Expression of recombinant proteins in Pichia pastoris. Appl Biochem Biotechnol 2007; 142:105–124.
31. Reljic R, Paul MJ, Arias MA. Cytokine therapy of tuberculosis at the crossroads. Expert Rev Respir Med 2009; 3:53–66.
32. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gamma delta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006; 177:4662–4669.
33. Dalmia N, Ramsay AJ. Prime–boost approaches to tuberculosis vaccine development. Expert Rev Vaccines 2012; 11:1221–1233.
34. Husain AA, Warke SR, Kalorey DR, Daginawala HF, Taori GM, Kashyap RS. Comparative evaluation of booster efficacies of BCG, Ag85B, and Ag85B peptides based vaccines to boost BCG induced immunity in BALB/c mice: a pilot study. Clin Exp Vaccine Res 2015; 4:83–87.
35. Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, Morshed S, et al. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine 2011; 29:2968–2977.
36. Lu L, Palaniyandi S, Zeng R, Bai Y, Liu X, Wang Y, et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol 2011; 85:10542–10553.
37. Mekhaiel DN, Czajkowsky DM, Andersen JT, Shi J, El-Faham M, Doenhoff M, et al. Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep 2011; 1:124.
38. Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, Shelton H, et al. Adjuvant free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol 2010; 85:3010–3014.